The Impact of Non-bone Metastatic Cancer on Musculoskeletal Health

1.

Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49. https://doi.org/10.3322/caac.21820.CrossRefPubMed

2.

Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95. https://doi.org/10.1016/S1470-2045(10)70218-7.CrossRefPubMed

3.

Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012;16(2):153–66. https://doi.org/10.1016/j.cmet.2012.06.011.CrossRefPubMed

4.

Melstrom LG, Melstrom KA Jr, Ding XZ, Adrian TE. Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia. Histol Histopathol. 2007;22(7):805–14. https://doi.org/10.14670/HH-22.805.CrossRefPubMed

5.

Bruggeman AR, Kamal AH, LeBlanc TW, Ma JD, Baracos VE, Roeland EJ. Cancer Cachexia: Beyond Weight Loss. J Oncol Pract. 2016;12(11):1163–71. https://doi.org/10.1200/JOP.2016.016832.CrossRefPubMed

6.

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29. https://doi.org/10.3322/caac.20138.CrossRefPubMed

7.

Thoresen L, Frykholm G, Lydersen S, Ulveland H, Baracos V, Prado CM, et al. Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. Clin Nutr. 2013;32(1):65–72. https://doi.org/10.1016/j.clnu.2012.05.009.CrossRefPubMed

8.

Argiles JM, Busquets S, Felipe A, Lopez-Soriano FJ. Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. Int J Biochem Cell Biol. 2005;37(5):1084–104. https://doi.org/10.1016/j.biocel.2004.10.003.CrossRefPubMed

9.

Gullett N, Rossi P, Kucuk O, Johnstone PA. Cancer-induced cachexia: a guide for the oncologist. J Soc Integr Oncol. 2009;7(4):155–69.PubMed

10.

Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27(6):793–9. https://doi.org/10.1016/j.clnu.2008.06.013.CrossRefPubMed

11.

Schmidt SF, Rohm M, Herzig S, Berriel DM. Cancer Cachexia: More Than Skeletal Muscle Wasting. Trends Cancer. 2018;4(12):849–60. https://doi.org/10.1016/j.trecan.2018.10.001.CrossRefPubMed

12.

McGovern J, Dolan RD, Horgan PG, Laird BJ, McMillan DC. Computed tomography-defined low skeletal muscle index and density in cancer patients: observations from a systematic review. J Cachexia Sarcopenia Muscle. 2021;12(6):1408–17. https://doi.org/10.1002/jcsm.12831.CrossRefPubMedPubMedCentral

13.

Buentzel J, Heinz J, Bleckmann A, Bauer C, Rover C, Bohnenberger H, et al. Sarcopenia as Prognostic Factor in Lung Cancer Patients: A Systematic Review and Meta-analysis. Anticancer Res. 2019;39(9):4603–12. https://doi.org/10.21873/anticanres.13640.CrossRefPubMed

14.

Zhu Y, Guo X, Zhang Q, Yang Y. Prognostic value of sarcopenia in patients with rectal cancer: A meta-analysis. PLoS ONE. 2022;17(6): e0270332. https://doi.org/10.1371/journal.pone.0270332.CrossRefPubMedPubMedCentral

15.

Waalboer RB, Meyer YM, Galjart B, Olthof PB, van Vugt JLA, Grunhagen DJ, Verhoef C. Sarcopenia and long-term survival outcomes after local therapy for colorectal liver metastasis: a meta-analysis. HPB (Oxford). 2022;24(1):9–16. https://doi.org/10.1016/j.hpb.2021.08.947.CrossRefPubMed

16.

Thormann M, Hinnerichs M, Barajas Ordonez F, Saalfeld S, Perrakis A, Croner R, et al. Sarcopenia is an Independent Prognostic Factor in Patients With Pancreatic Cancer - a Meta-analysis. Acad Radiol. 2023;30(8):1552–61. https://doi.org/10.1016/j.acra.2022.10.025.CrossRefPubMed

17.

Ubachs J, Ziemons J, Minis-Rutten IJG, Kruitwagen R, Kleijnen J, Lambrechts S, et al. Sarcopenia and ovarian cancer survival: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2019;10(6):1165–74. https://doi.org/10.1002/jcsm.12468.CrossRefPubMedPubMedCentral

18.

Fang P, Zhou J, Xiao X, Yang Y, Luan S, Liang Z, et al. The prognostic value of sarcopenia in oesophageal cancer: A systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2023;14(1):3–16. https://doi.org/10.1002/jcsm.13126.CrossRefPubMed

19.

Couderc AL, Liuu E, Boudou-Rouquette P, Poisson J, Frelaut M, Montegut C, et al. Pre-Therapeutic Sarcopenia among Cancer Patients: An Up-to-Date Meta-Analysis of Prevalence and Predictive Value during Cancer Treatment. Nutrients. 2023;15(5):1193. https://doi.org/10.3390/nu15051193.

20.

Chen XD, Zeng YP, Huang YS, Xu JX, Meng WY, Wang X, et al. Preoperative Cachexia predicts poor outcomes in young rather than elderly gastric cancer patients: a prospective study. Cancer Management and Research. 2019;11:8101–10. https://doi.org/10.2147/Cmar.S213237.CrossRefPubMedPubMedCentral

21.

Loumaye A, de Barsy M, Nachit M, Lause P, Frateur L, van Maanen A, et al. Role of Activin A and myostatin in human cancer cachexia. J Clin Endocrinol Metab. 2015;100(5):2030–8. https://doi.org/10.1210/jc.2014-4318.CrossRefPubMed

22.

Puig-Vilanova E, Rodriguez DA, Lloreta J, Ausin P, Pascual-Guardia S, Broquetas J, et al. Oxidative stress, redox signaling pathways, and autophagy in cachectic muscles of male patients with advanced COPD and lung cancer. Free Radic Biol Med. 2015;79:91–108. https://doi.org/10.1016/j.freeradbiomed.2014.11.006.CrossRefPubMed

23.

Op den Kamp CM, Langen RC, Snepvangers FJ, de Theije CC, Schellekens JM, Laugs F, et al. Nuclear transcription factor kappa B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia. Am J Clin Nutr. 2013;98(3):738–48. https://doi.org/10.3945/ajcn.113.058388.CrossRefPubMed

24.

Op den Kamp CM, Gosker HR, Lagarde S, Tan DY, Snepvangers FJ, Dingemans AM, et al. Preserved muscle oxidative metabolic phenotype in newly diagnosed non-small cell lung cancer cachexia. J Cachexia Sarcopenia Muscle. 2015;6(2):164–73. https://doi.org/10.1002/jcsm.12007.CrossRefPubMedPubMedCentral

25.

Weber MA, Krakowski-Roosen H, Schroder L, Kinscherf R, Krix M, Kopp-Schneider A, et al. Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia. Acta Oncol. 2009;48(1):116–24. https://doi.org/10.1080/02841860802130001.CrossRefPubMed

26.

Stephens NA, Gray C, MacDonald AJ, Tan BH, Gallagher IJ, Skipworth RJ, et al. Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function. Clin Nutr. 2012;31(4):499–505. https://doi.org/10.1016/j.clnu.2011.12.008.CrossRefPubMed

27.

Santagnello SB, Martins FM, de Oliveira Junior GN, de Sousa JFR, Nomelini RS, Murta EFC, Orsatti FL. Resistance Training-Induced Gains in Muscle Strength and Power Mediate the Improvement in Walking Speed in Middle-Aged Women Who Are Breast Cancer Survivors. J Strength Cond Res. 2024;38(4):773–82. https://doi.org/10.1519/JSC.0000000000004020.CrossRefPubMed

28.

Zaheer S, LeBoff MS. Osteoporosis: Prevention and Treatment. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al., editors. Endotext. South Dartmouth (MA):MDText.com, Inc.; 2000.

29.

Pin F, Bonewald LF, Bonetto A. Role of myokines and osteokines in cancer cachexia. Exp Biol Med (Maywood). 2021;246(19):2118–27. https://doi.org/10.1177/15353702211009213.CrossRefPubMed

30.

Mazziotti G, Lania AG, Lagana M, Berruti A. Prediction of fragility fractures in men with prostate cancer under androgen deprivation therapy: the importance of a multidisciplinary approach using a mini-invasive diagnostic tool. Endocrine. 2023. https://doi.org/10.1007/s12020-023-03613-2.CrossRefPubMed

31.

Suvannasankha A, Chirgwin JM. Role of bone-anabolic agents in the treatment of breast cancer bone metastases. Breast Cancer Res. 2014;16(6):484. https://doi.org/10.1186/s13058-014-0484-9.CrossRefPubMedPubMedCentral

32.

Hung YC, Yeh LS, Chang WC, Lin CC, Kao CH. Prospective study of decreased bone mineral density in patients with cervical cancer without bone metastases: a preliminary report. Jpn J Clin Oncol. 2002;32(10):422–4. https://doi.org/10.1093/jjco/hyf082.CrossRefPubMed

33.

Nisha Y, Dubashi B, Bobby Z, Sahoo JP, Kayal S, Ananthakrishnan R, et al. Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy. J Bone Miner Metab. 2023;41(5):682–92. https://doi.org/10.1007/s00774-023-01444-9.CrossRefPubMed

34.

Watanabe J, Saitsu A, Miki A, Kotani K, Sata N. Prognostic value of preoperative low bone mineral density in patients with digestive cancers: a systematic review and meta-analysis. Arch Osteoporos. 2022;17(1):33. https://doi.org/10.1007/s11657-022-01060-6.CrossRefPubMedPubMedCentral

35.

•• Cameron ME, Underwood PW, Williams IE, George TJ, Judge SM, Yarrow JF, et al. Osteopenia is associated with wasting in pancreatic adenocarcinoma and predicts survival after surgery. Cancer Med. 2022;11(1):50–60. https://doi.org/10.1002/cam4.4416. An important study which demonstrated that osteopenia was the strongest predictor of survival in patients with pancreatic cancer.CrossRefPubMed

36.

Taniai T, Haruki K, Yanagaki M, Igarashi Y, Furukawa K, Onda S, et al. Osteosarcopenia predicts poor prognosis for patients with intrahepatic cholangiocarcinoma after hepatic resection. Surg Today. 2023;53(1):82–9. https://doi.org/10.1007/s00595-022-02550-3.CrossRefPubMed

37.

Kanis JA, McCloskey EV, Powles T, Paterson AH, Ashley S, Spector T. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer. 1999;79(7–8):1179–81. https://doi.org/10.1038/sj.bjc.6690188.CrossRefPubMedPubMedCentral

38.

Edwards BJ, Sun M, Zhang X, Holmes HM, Song J, Khalil P, et al. Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience. Support Care Cancer. 2018;26(5):1561–8. https://doi.org/10.1007/s00520-017-3962-7.CrossRefPubMed

39.

Gong IY, Chan KKW, Lipscombe LL, Cheung MC, Mozessohn L. Fracture risk among patients with cancer compared to individuals without cancer: a population-based study. Br J Cancer. 2023;129(4):665–71. https://doi.org/10.1038/s41416-023-02353-4.CrossRefPubMed

40.

Roeland EJ, Bohlke K, Baracos VE, Bruera E, Del Fabbro E, Dixon S, et al. Management of Cancer Cachexia: ASCO Guideline. J Clin Oncol. 2020;38(21):2438–53. https://doi.org/10.1200/JCO.20.00611.CrossRefPubMed

41.

Clemente-Suarez VJ, Redondo-Florez L, Rubio-Zarapuz A, Martinez-Guardado I, Navarro-Jimenez E, Tornero-Aguilera JF. Nutritional and Exercise Interventions in Cancer-Related Cachexia: An Extensive Narrative Review. Int J Environ Res Public Health. 2022;19(8):4604. https://doi.org/10.3390/ijerph19084604.

42.

Setiawan T, Sari IN, Wijaya YT, Julianto NM, Muhammad JA, Lee H, et al. Cancer cachexia: molecular mechanisms and treatment strategies. J Hematol Oncol. 2023;16(1):54. https://doi.org/10.1186/s13045-023-01454-0.CrossRefPubMedPubMedCentral

43.

Marceca GP, Londhe P, Calore F. Management of Cancer Cachexia: Attempting to Develop New Pharmacological Agents for New Effective Therapeutic Options. Front Oncol. 2020;10:298. https://doi.org/10.3389/fonc.2020.00298.CrossRefPubMedPubMedCentral

44.

Senesse P, Isambert A, Janiszewski C, Fiore S, Flori N, Poujol S, et al. Management of Cancer Cachexia and Guidelines Implementation in a Comprehensive Cancer Center: A Physician-Led Cancer Nutrition Program Adapted to the Practices of a Country. J Pain Symptom Manage. 2017;54(3):387-93 e3. https://doi.org/10.1016/j.jpainsymman.2017.01.010.CrossRefPubMed

45.

Barreto R, Waning DL, Gao H, Liu Y, Zimmers TA, Bonetto A. Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. Oncotarget. 2016;7(28):43442–60. https://doi.org/10.18632/oncotarget.9779.CrossRefPubMedPubMedCentral

46.

Essex AL, Pin F, Huot JR, Bonewald LF, Plotkin LI, Bonetto A. Bisphosphonate Treatment Ameliorates Chemotherapy-Induced Bone and Muscle Abnormalities in Young Mice. Front Endocrinol (Lausanne). 2019;10:809. https://doi.org/10.3389/fendo.2019.00809.CrossRefPubMedPubMedCentral

47.

Huot JR, Novinger LJ, Pin F, Narasimhan A, Zimmers TA, O'Connell TM, Bonetto A. Formation of colorectal liver metastases induces musculoskeletal and metabolic abnormalities consistent with exacerbated cachexia. JCI Insight. 2020;5(9). https://doi.org/10.1172/jci.insight.136687.

48.

Huot JR, Pin F, Essex AL, Bonetto A. MC38 Tumors Induce Musculoskeletal Defects in Colorectal Cancer. Int J Mol Sci. 2021;22(3). https://doi.org/10.3390/ijms22031486.

49.

Huot JR, Novinger LJ, Pin F, Bonetto A. HCT116 colorectal liver metastases exacerbate muscle wasting in a mouse model for the study of colorectal cancer cachexia. Dis Model Mech. 2020;13(1). https://doi.org/10.1242/dmm.043166.

50.

Neyroud D, Laitano O, Dasgupta A, Lopez C, Schmitt RE, Schneider JZ, et al. Blocking muscle wasting via deletion of the muscle-specific E3 ligase MuRF1 impedes pancreatic tumor growth. Commun Biol. 2023;6(1):519. https://doi.org/10.1038/s42003-023-04902-2.CrossRefPubMedPubMedCentral

51.

Belcher DJ, Guitart M, Hain B, Kim HG, Waning D, Barreiro E, Nader GA. LP07 and LLC preclinical models of lung cancer induce divergent anabolic deficits and expression of pro-inflammatory effectors of muscle wasting. J Appl Physiol. 2022;133(6):1260–72. https://doi.org/10.1152/japplphysiol.00246.2022. (1985).CrossRefPubMedPubMedCentral

52.

Pin F, Barreto R, Kitase Y, Mitra S, Erne CE, Novinger LJ, et al. Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia. J Cachexia Sarcopenia Muscle. 2018;9(4):685–700. https://doi.org/10.1002/jcsm.12311.CrossRefPubMedPubMedCentral

53.

Huot JR, Pin F, Bonetto A. Muscle weakness caused by cancer and chemotherapy is associated with loss of motor unit connectivity. Am J Cancer Res. 2021;11(6):2990–3001.PubMedPubMedCentral

54.

Huot JR, Novinger LJ, Pin F, Narasimhan A, Zimmers TA, O’Connell TM, Bonetto A. Formation of colorectal liver metastases induces musculoskeletal and metabolic abnormalities consistent with exacerbated cachexia. JCI Insight. 2020. https://doi.org/10.1172/jci.insight.136687.CrossRefPubMedPubMedCentral

55.

Huot JR, Novinger LJ, Pin F, Bonetto A. HCT116 colorectal liver metastases exacerbate muscle wasting in a mouse model for the study of colorectal cancer cachexia. Dis Model Mech. 2020. https://doi.org/10.1242/dmm.043166.CrossRefPubMedPubMedCentral

56.

Chen JA, Splenser A, Guillory B, Luo J, Mendiratta M, Belinova B, et al. Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. J Cachexia Sarcopenia Muscle. 2015;6(2):132–43. https://doi.org/10.1002/jcsm.12023.CrossRefPubMedPubMedCentral

57.

• Pin F, Jones AJ, Huot JR, Narasimhan A, Zimmers TA, Bonewald LF, Bonetto A. RANKL Blockade Reduces Cachexia and Bone Loss Induced by Non-Metastatic Ovarian Cancer in Mice. J Bone Miner Res. 2022;37(3):381–96. https://doi.org/10.1002/jbmr.4480. This study shows that targeting RANKL preserves musculoskeletal health in a mouse model of ovarian cancer.CrossRefPubMed

58.

Mulder SE, Dasgupta A, King RJ, Abrego J, Attri KS, Murthy D, et al. JNK signaling contributes to skeletal muscle wasting and protein turnover in pancreatic cancer cachexia. Cancer Lett. 2020;491:70–7. https://doi.org/10.1016/j.canlet.2020.07.025.CrossRefPubMedPubMedCentral

59.

VanderVeen BN, Hardee JP, Fix DK, Carson JA. Skeletal muscle function during the progression of cancer cachexia in the male Apc(Min/+) mouse. J Appl Physiol. 2018;124(3):684–95. https://doi.org/10.1152/japplphysiol.00897.2017. (1985).CrossRefPubMed

60.

• Delfinis LJ, Bellissimo CA, Gandhi S, DiBenedetto SN, Garibotti MC, Thuhan AK, et al. Muscle weakness precedes atrophy during cancer cachexia and is linked to muscle-specific mitochondrial stress. JCI Insight. 2022;7(24). https://doi.org/10.1172/jci.insight.155147.An interesting study suggesting that cancer-induced muscle weakness occurs prior to the onset of cancer-induced muscle wasting.

61.

Allen MD, Dalton BH, Gilmore KJ, McNeil CJ, Doherty TJ, Rice CL, Power GA. Neuroprotective effects of exercise on the aging human neuromuscular system. Exp Gerontol. 2021;152: 111465. https://doi.org/10.1016/j.exger.2021.111465.CrossRefPubMed

62.

Blasco A, Gras S, Modol-Caballero G, Tarabal O, Casanovas A, Piedrafita L, et al. Motoneuron deafferentation and gliosis occur in association with neuromuscular regressive changes during ageing in mice. J Cachexia Sarcopenia Muscle. 2020;11(6):1628–60. https://doi.org/10.1002/jcsm.12599.CrossRefPubMedPubMedCentral

63.

Huijbers MG, Marx A, Plomp JJ, Le Panse R, Phillips WD. Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):163–75. https://doi.org/10.1016/S1474-4422(21)00357-4.CrossRefPubMed

64.

Verma S, Khurana S, Vats A, Sahu B, Ganguly NK, Chakraborti P, et al. Neuromuscular Junction Dysfunction in Amyotrophic Lateral Sclerosis. Mol Neurobiol. 2022;59(3):1502–27. https://doi.org/10.1007/s12035-021-02658-6.CrossRefPubMed

65.

Sartori R, Hagg A, Zampieri S, Armani A, Winbanks CE, Viana LR, et al. Perturbed BMP signaling and denervation promote muscle wasting in cancer cachexia. Sci Transl Med. 2021;13(605). https://doi.org/10.1126/scitranslmed.aay9592.

66.

Daou N, Hassani M, Matos E, De Castro GS, Costa RGF, Seelaender M, et al. Displaced Myonuclei in Cancer Cachexia Suggest Altered Innervation. Int J Mol Sci. 2020;21(3). https://doi.org/10.3390/ijms21031092.

67.

Bonetto A, Kays JK, Parker VA, Matthews RR, Barreto R, Puppa MJ, et al. Differential Bone Loss in Mouse Models of Colon Cancer Cachexia. Front Physiol. 2016;7:679. https://doi.org/10.3389/fphys.2016.00679.CrossRefPubMed

68.

Choi E, Carruthers K, Zhang L, Thomas N, Battaglino RA, Morse LR, Widrick JJ. Concurrent muscle and bone deterioration in a murine model of cancer cachexia. Physiol Rep. 2013;1(6): e00144. https://doi.org/10.1002/phy2.144.CrossRefPubMedPubMedCentral

69.

Zhang Q, Sun X, Yang J, Ding H, LeBrun D, Ding K, et al. ZIP4 silencing improves bone loss in pancreatic cancer. Oncotarget. 2015;6(28):26041–51. https://doi.org/10.18632/oncotarget.4667.CrossRefPubMedPubMedCentral

70.

Huot JR, Pin F, Narasimhan A, Novinger LJ, Keith AS, Zimmers TA, et al. ACVR2B antagonism as a countermeasure to multi-organ perturbations in metastatic colorectal cancer cachexia. J Cachexia Sarcopenia Muscle. 2020;11(6):1779–98. https://doi.org/10.1002/jcsm.12642.CrossRefPubMedPubMedCentral

71.

•• Pin F, Prideaux M, Huot JR, Essex AL, Plotkin LI, Bonetto A, Bonewald LF. Non-bone metastatic cancers promote osteocyte-induced bone destruction. Cancer Lett. 2021;520:80–90. https://doi.org/10.1016/j.canlet.2021.06.030. This important work demonstrates that osteocytic bone destruction can occur in the absence of skeletal metastases.CrossRefPubMedPubMedCentral

72.

Whyne CM, Ferguson D, Clement A, Rangrez M, Hardisty M. Biomechanical Properties of Metastatically Involved Osteolytic Bone. Curr Osteoporos Rep. 2020;18(6):705–15. https://doi.org/10.1007/s11914-020-00633-z.CrossRefPubMed

73.

Arrington SA, Schoonmaker JE, Damron TA, Mann KA, Allen MJ. Temporal changes in bone mass and mechanical properties in a murine model of tumor osteolysis. Bone. 2006;38(3):359–67. https://doi.org/10.1016/j.bone.2005.09.013.CrossRefPubMed

74.

Shimonty A, Bonewald LF, Huot JR. Metabolic Health and Disease: A Role of Osteokines? Calcif Tissue Int. 2023;113(1):21–38. https://doi.org/10.1007/s00223-023-01093-0.CrossRefPubMed

75.

Huang Q, Wu M, Wu X, Zhang Y, Xia Y. Muscle-to-tumor crosstalk: The effect of exercise-induced myokine on cancer progression. Biochim Biophys Acta Rev Cancer. 2022;1877(5): 188761. https://doi.org/10.1016/j.bbcan.2022.188761.CrossRefPubMed

76.

Sutandyo N, Cintakaweni DMW, Setiawan L, Hariani R, Utami N. Association of Body Composition and Handgrip Strength with Interleukin-6 (IL-6) and Vitamin D Level in Cancer Patients. Int J Gen Med. 2023;16:1995–2001. https://doi.org/10.2147/IJGM.S388457.CrossRefPubMedPubMedCentral

77.

Wan Q, Wang Z, Zhao R, Tu T, Shen X, Shen Y, et al. CT-determined low skeletal muscle mass predicts worse overall survival of gastric cancer in patients with cachexia. Cancer Med. 2023;12(2):1492–500. https://doi.org/10.1002/cam4.5040.CrossRefPubMed

78.

Kays JK, Koniaris LG, Cooper CA, Pili R, Jiang G, Liu Y, Zimmers TA. The Combination of Low Skeletal Muscle Mass and High Tumor Interleukin-6 Associates with Decreased Survival in Clear Cell Renal Cell Carcinoma. Cancers (Basel). 2020;12(6). https://doi.org/10.3390/cancers12061605.

79.

Miura T, Mitsunaga S, Ikeda M, Shimizu S, Ohno I, Takahashi H, et al. Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels. Pancreas. 2015;44(5):756–63. https://doi.org/10.1097/MPA.0000000000000335.CrossRefPubMed

80.

Bonetto A, Aydogdu T, Jin X, Zhang Z, Zhan R, Puzis L, et al. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab. 2012;303(3):E410–21. https://doi.org/10.1152/ajpendo.00039.2012.CrossRefPubMedPubMedCentral

81.

Bonetto A, Aydogdu T, Kunzevitzky N, Guttridge DC, Khuri S, Koniaris LG, Zimmers TA. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS ONE. 2011;6(7): e22538. https://doi.org/10.1371/journal.pone.0022538.CrossRefPubMedPubMedCentral

82.

Baltgalvis KA, Berger FG, Pena MM, Davis JM, White JP, Carson JA. Muscle wasting and interleukin-6-induced atrogin-I expression in the cachectic Apc ( Min/+ ) mouse. Pflugers Arch. 2009;457(5):989–1001. https://doi.org/10.1007/s00424-008-0574-6.CrossRefPubMed

83.

White JP, Baynes JW, Welle SL, Kostek MC, Matesic LE, Sato S, Carson JA. The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min/+) mouse. PLoS ONE. 2011;6(9): e24650. https://doi.org/10.1371/journal.pone.0024650.CrossRefPubMedPubMedCentral

84.

White JP, Puppa MJ, Gao S, Sato S, Welle SL, Carson JA. Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK. Am J Physiol Endocrinol Metab. 2013;304(10):E1042–52. https://doi.org/10.1152/ajpendo.00410.2012.CrossRefPubMedPubMedCentral

85.

Rupert JE, Narasimhan A, Jengelley DHA, Jiang Y, Liu J, Au E, et al. Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia. J Exp Med. 2021;218(6). https://doi.org/10.1084/jem.20190450.

86.

Peruzzi B, Cappariello A, Del Fattore A, Rucci N, De Benedetti F, Teti A. c-Src and IL-6 inhibit osteoblast differentiation and integrate IGFBP5 signalling. Nat Commun. 2012;3:630. https://doi.org/10.1038/ncomms1651.CrossRefPubMed

87.

Kaneshiro S, Ebina K, Shi K, Higuchi C, Hirao M, Okamoto M, et al. IL-6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitro. J Bone Miner Metab. 2014;32(4):378–92. https://doi.org/10.1007/s00774-013-0514-1.CrossRefPubMed

88.

De Benedetti F, Rucci N, Del Fattore A, Peruzzi B, Paro R, Longo M, et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum. 2006;54(11):3551–63. https://doi.org/10.1002/art.22175.CrossRefPubMed

89.

Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 1992;257(5066):88–91. https://doi.org/10.1126/science.1621100.CrossRefPubMed

90.

Wang C, Tian L, Zhang K, Chen Y, Chen X, Xie Y, et al. Interleukin-6 gene knockout antagonizes high-fat-induced trabecular bone loss. J Mol Endocrinol. 2016;57(3):161–70. https://doi.org/10.1530/JME-16-0076.CrossRefPubMed

91.

Harmer D, Falank C, Reagan MR. Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma. Front Endocrinol (Lausanne). 2018;9:788. https://doi.org/10.3389/fendo.2018.00788.CrossRefPubMed

92.

Ara T, Declerck YA. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer. 2010;46(7):1223–31. https://doi.org/10.1016/j.ejca.2010.02.026.CrossRefPubMedPubMedCentral

93.

Tumminello FM, Badalamenti G, Incorvaia L, Fulfaro F, D’Amico C, Leto G. Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C. Med Oncol. 2009;26(1):10–5. https://doi.org/10.1007/s12032-008-9070-2.CrossRefPubMed

94.

Noman AS, Uddin M, Chowdhury AA, Nayeem MJ, Raihan Z, Rashid MI, et al. Serum sonic hedgehog (SHH) and interleukin-(IL-6) as dual prognostic biomarkers in progressive metastatic breast cancer. Sci Rep. 2017;7(1):1796. https://doi.org/10.1038/s41598-017-01268-4.CrossRefPubMedPubMedCentral

95.

Huang X, Ni B, Li Q, Liu M, Zhao M, Zhang Y, et al. Association between Postmenopausal Osteoporosis and IL-6、TNF-alpha: A Systematic Review and A Meta-analysis. Comb Chem High Throughput Screen. 2024. https://doi.org/10.2174/0113862073262645231121025911.CrossRefPubMed

96.

Xiong J, Piemontese M, Onal M, Campbell J, Goellner JJ, Dusevich V, et al. Osteocytes, not Osteoblasts or Lining Cells, are the Main Source of the RANKL Required for Osteoclast Formation in Remodeling Bone. PLoS ONE. 2015;10(9): e0138189. https://doi.org/10.1371/journal.pone.0138189.CrossRefPubMedPubMedCentral

97.

Xiong J, O’Brien CA. Osteocyte RANKL: new insights into the control of bone remodeling. J Bone Miner Res. 2012;27(3):499–505. https://doi.org/10.1002/jbmr.1547.CrossRefPubMed

98.

Ono T, Hayashi M, Sasaki F, Nakashima T. RANKL biology: bone metabolism, the immune system, and beyond. Inflamm Regen. 2020;40:2. https://doi.org/10.1186/s41232-019-0111-3.CrossRefPubMedPubMedCentral

99.

Kiechl S, Schramek D, Widschwendter M, Fourkala EO, Zaikin A, Jones A, et al. Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer. Oncotarget. 2017;8(3):3811–25. https://doi.org/10.18632/oncotarget.14013.CrossRefPubMed

100.

Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM, Karin M. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature. 2011;470(7335):548–53. https://doi.org/10.1038/nature09707.CrossRefPubMedPubMedCentral

101.

Galvano A, Scaturro D, Badalamenti G, Incorvaia L, Rizzo S, Castellana L, et al. Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials. J Bone Oncol. 2019;18: 100252. https://doi.org/10.1016/j.jbo.2019.100252.CrossRefPubMedPubMedCentral

102.

Dufresne SS, Dumont NA, Boulanger-Piette A, Fajardo VA, Gamu D, Kake-Guena SA, et al. Muscle RANK is a key regulator of Ca2+ storage, SERCA activity, and function of fast-twitch skeletal muscles. Am J Physiol Cell Physiol. 2016;310(8):C663–72. https://doi.org/10.1152/ajpcell.00285.2015.CrossRefPubMedPubMedCentral

103.

Xiong J, Le Y, Rao Y, Zhou L, Hu Y, Guo S, Sun Y. RANKL Mediates Muscle Atrophy and Dysfunction in a Cigarette Smoke-induced Model of Chronic Obstructive Pulmonary Disease. Am J Respir Cell Mol Biol. 2021;64(5):617–28. https://doi.org/10.1165/rcmb.2020-0449OC.CrossRefPubMed

104.

Hamoudi D, Marcadet L, Piette Boulanger A, Yagita H, Bouredji Z, Argaw A, Frenette J. An anti-RANKL treatment reduces muscle inflammation and dysfunction and strengthens bone in dystrophic mice. Hum Mol Genet. 2019;28(18):3101–12. https://doi.org/10.1093/hmg/ddz124.CrossRefPubMed

105.

Martin TJ. Osteoblast-derived PTHrP is a physiological regulator of bone formation. J Clin Invest. 2005;115(9):2322–4. https://doi.org/10.1172/jci26239.CrossRefPubMedPubMedCentral

106.

Jahn K, Kelkar S, Zhao H, Xie Y, Tiede-Lewis LM, Dusevich V, et al. Osteocytes Acidify Their Microenvironment in Response to PTHrP In Vitro and in Lactating Mice In Vivo. J Bone Miner Res. 2017;32(8):1761–72. https://doi.org/10.1002/jbmr.3167.CrossRefPubMed

107.

Deftos LJ, Barken I, Burton DW, Hoffman RM, Geller J. Direct evidence that PTHrP expression promotes prostate cancer progression in bone. Biochem Biophys Res Commun. 2005;327(2):468–72. https://doi.org/10.1016/j.bbrc.2004.11.162.CrossRefPubMed

108.

Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest. 1996;98(7):1544–9. https://doi.org/10.1172/JCI118947.CrossRefPubMedPubMedCentral

109.

Zhao Y, Su S, Li X. Parathyroid Hormone-Related Protein/Parathyroid Hormone Receptor 1 Signaling in Cancer and Metastasis. Cancers (Basel). 2023;15(7). https://doi.org/10.3390/cancers15071982.

110.

Edwards CM, Johnson RW. From Good to Bad: The Opposing Effects of PTHrP on Tumor Growth, Dormancy, and Metastasis Throughout Cancer Progression. Front Oncol. 2021;11: 644303. https://doi.org/10.3389/fonc.2021.644303.CrossRefPubMedPubMedCentral

111.

Hong N, Yoon HJ, Lee YH, Kim HR, Lee BW, Rhee Y, et al. Serum PTHrP Predicts Weight Loss in Cancer Patients Independent of Hypercalcemia, Inflammation, and Tumor Burden. J Clin Endocrinol Metab. 2016;101(3):1207–14. https://doi.org/10.1210/jc.2015-3785.CrossRefPubMed

112.

Iresjo BM, Kir S, Lundholm K. Parathyroid hormone related protein (PTHrP) in patients with pancreatic carcinoma and overt signs of disease progression and host tissue wasting. Transl Oncol. 2023;36: 101752. https://doi.org/10.1016/j.tranon.2023.101752.CrossRefPubMedPubMedCentral

113.

Onuma E, Tsunenari T, Saito H, Sato K, Yamada-Okabe H, Ogata E. Parathyroid hormone-related protein (PTHrP) as a causative factor of cancer-associated wasting: possible involvement of PTHrP in the repression of locomotor activity in rats bearing human tumor xenografts. Int J Cancer. 2005;116(3):471–8. https://doi.org/10.1002/ijc.21038.CrossRefPubMed

114.

Kir S, White JP, Kleiner S, Kazak L, Cohen P, Baracos VE, Spiegelman BM. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature. 2014;513(7516):100–4. https://doi.org/10.1038/nature13528.CrossRefPubMedPubMedCentral

115.

Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, Reeve J. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005;19(13):1842–4. https://doi.org/10.1096/fj.05-4221fje.CrossRefPubMed

116.

Atkins GJ, Rowe PS, Lim HP, Welldon KJ, Ormsby R, Wijenayaka AR, et al. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res. 2011;26(7):1425–36. https://doi.org/10.1002/jbmr.345.CrossRefPubMed

117.

Yavropoulou MP, van Lierop AH, Hamdy NA, Rizzoli R, Papapoulos SE. Serum sclerostin levels in Paget’s disease and prostate cancer with bone metastases with a wide range of bone turnover. Bone. 2012;51(1):153–7. https://doi.org/10.1016/j.bone.2012.04.016.CrossRefPubMed

118.

Terpos E, Christoulas D, Katodritou E, Bratengeier C, Gkotzamanidou M, Michalis E, et al. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy. Int J Cancer. 2012;131(6):1466–71. https://doi.org/10.1002/ijc.27342.CrossRefPubMed

119.

Zhu M, Liu C, Li S, Zhang S, Yao Q, Song Q. Sclerostin induced tumor growth, bone metastasis and osteolysis in breast cancer. Sci Rep. 2017;7(1):11399. https://doi.org/10.1038/s41598-017-11913-7.CrossRefPubMedPubMedCentral

120.

Hesse E, Schroder S, Brandt D, Pamperin J, Saito H, Taipaleenmaki H. Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness. JCI Insight. 2019;5(9). https://doi.org/10.1172/jci.insight.125543.

121.

Kim JA, Roh E, Hong SH, Lee YB, Kim NH, Yoo HJ, et al. Association of serum sclerostin levels with low skeletal muscle mass: The Korean Sarcopenic Obesity Study (KSOS). Bone. 2019;128: 115053. https://doi.org/10.1016/j.bone.2019.115053.CrossRefPubMed

122.

Medeiros MC, Rocha N, Bandeira E, Dantas I, Chaves C, Oliveira M, Bandeira F. Serum Sclerostin, Body Composition, and Sarcopenia in Hemodialysis Patients with Diabetes. Int J Nephrol. 2020;2020:4596920. https://doi.org/10.1155/2020/4596920.CrossRefPubMedPubMedCentral

123.

Huang J, Romero-Suarez S, Lara N, Mo C, Kaja S, Brotto L, et al. Crosstalk between MLO-Y4 osteocytes and C2C12 muscle cells is mediated by the Wnt/β-catenin pathway. JBMR Plus. 2017;1(2):86–100. https://doi.org/10.1002/jbm4.10015.CrossRefPubMedPubMedCentral

124.

Bonewald LF, Mundy GR. Role of transforming growth factor-beta in bone remodeling. Clin Orthop Relat Res. 1990;250:261–76.CrossRef

125.

Peng L, Yuan XQ, Zhang CY, Ye F, Zhou HF, Li WL, et al. High TGF-beta1 expression predicts poor disease prognosis in hepatocellular carcinoma patients. Oncotarget. 2017;8(21):34387–97. https://doi.org/10.18632/oncotarget.16166.CrossRefPubMedPubMedCentral

126.

Teicher BA. Malignant cells, directors of the malignant process: role of transforming growth factor-beta. Cancer Metastasis Rev. 2001;20(1–2):133–43. https://doi.org/10.1023/a:1013177011767.CrossRefPubMed

127.

Lima J, Simoes E, de Castro G, Morais M, de Matos-Neto EM, Alves MJ, et al. Tumour-derived transforming growth factor-beta signalling contributes to fibrosis in patients with cancer cachexia. J Cachexia Sarcopenia Muscle. 2019;10(5):1045–59. https://doi.org/10.1002/jcsm.12441.CrossRefPubMedPubMedCentral

128.

Waning DL, Mohammad KS, Reiken S, Xie W, Andersson DC, John S, et al. Excess TGF-β mediates muscle weakness associated with bone metastases in mice. Nat Med. 2015;21(11):1262–71. https://doi.org/10.1038/nm.3961.CrossRefPubMedPubMedCentral

129.

Dasgupta A, Gibbard DF, Schmitt RE, Arneson-Wissink PC, Ducharme AM, Bruinsma ES, et al. A TGF-beta/KLF10 signaling axis regulates atrophy-associated genes to induce muscle wasting in pancreatic cancer. Proc Natl Acad Sci U S A. 2023;120(34): e2215095120. https://doi.org/10.1073/pnas.2215095120.CrossRefPubMedPubMedCentral

130.

Fuller K, Bayley KE, Chambers TJ. Activin A is an essential cofactor for osteoclast induction. Biochem Biophys Res Commun. 2000;268(1):2–7. https://doi.org/10.1006/bbrc.2000.2075.CrossRefPubMed

131.

Gaddy-Kurten D, Coker JK, Abe E, Jilka RL, Manolagas SC. Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures. Endocrinology. 2002;143(1):74–83. https://doi.org/10.1210/endo.143.1.8580.CrossRefPubMed

132.

Chantry AD, Heath D, Mulivor AW, Pearsall S, Baud’huin M, Coulton L, et al. Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. J Bone Miner Res. 2010;25(12):2633–46. https://doi.org/10.1002/jbmr.142.CrossRefPubMed

133.

Loumaye A, de Barsy M, Nachit M, Lause P, van Maanen A, Trefois P, et al. Circulating Activin A predicts survival in cancer patients. J Cachexia Sarcopenia Muscle. 2017;8(5):768–77. https://doi.org/10.1002/jcsm.12209.CrossRefPubMedPubMedCentral

134.

Lerner L, Hayes TG, Tao N, Krieger B, Feng B, Wu Z, et al. Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients. J Cachexia Sarcopenia Muscle. 2015;6(4):317–24. https://doi.org/10.1002/jcsm.12033.CrossRefPubMedPubMedCentral

135.

Leto G, Incorvaia L, Badalamenti G, Tumminello FM, Gebbia N, Flandina C, et al. Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis. 2006;23(2):117–22. https://doi.org/10.1007/s10585-006-9010-5.CrossRefPubMed

136.

Benny Klimek ME, Aydogdu T, Link MJ, Pons M, Koniaris LG, Zimmers TA. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem Biophys Res Commun. 2010;391(3):1548–54. https://doi.org/10.1016/j.bbrc.2009.12.123.CrossRefPubMed

137.

Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010;142(4):531–43. https://doi.org/10.1016/j.cell.2010.07.011.CrossRefPubMed

138.

Talbert EE, Guttridge DC. Emerging signaling mediators in the anorexia-cachexia syndrome of cancer. Trends Cancer. 2022;8(5):397–403. https://doi.org/10.1016/j.trecan.2022.01.004.CrossRefPubMedPubMedCentral

139.

Suriben R, Chen M, Higbee J, Oeffinger J, Ventura R, Li B, et al. Antibody-mediated inhibition of GDF15-GFRAL activity reverses cancer cachexia in mice. Nat Med. 2020;26(8):1264–70. https://doi.org/10.1038/s41591-020-0945-x.CrossRefPubMed

140.

Kim-Muller JY, Song L, LaCarubba PB, Pashos E, Li X, Rinaldi A, et al. GDF15 neutralization restores muscle function and physical performance in a mouse model of cancer cachexia. Cell Rep. 2023;42(1): 111947. https://doi.org/10.1016/j.celrep.2022.111947.CrossRefPubMed

141.

Teawtrakul N, Chansai S, Yamsri S, Chansung K, Wanitpongpun C, Lanamtieng T, et al. The association of growth differentiation factor-15 levels and osteoporosis in patients with thalassemia. Am J Med Sci. 2023;366(2):96–101. https://doi.org/10.1016/j.amjms.2023.05.002.CrossRefPubMed

142.

Hong SW, Kang JH. Growth differentiation factor-15 as a modulator of bone and muscle metabolism. Front Endocrinol (Lausanne). 2022;13: 948176. https://doi.org/10.3389/fendo.2022.948176.CrossRefPubMed

143.

Selander KS, Brown DA, Sequeiros GB, Hunter M, Desmond R, Parpala T, et al. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases. Cancer Epidemiol Biomarkers Prev. 2007;16(3):532–7. https://doi.org/10.1158/1055-9965.EPI-06-0841.CrossRefPubMed

144.

Wakchoure S, Swain TM, Hentunen TA, Bauskin AR, Brown DA, Breit SN, et al. Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss. Prostate. 2009;69(6):652–61. https://doi.org/10.1002/pros.20913.CrossRefPubMed

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The Impact of Non-bone Metastatic Cancer on Musculoskeletal Health

Abstract

Purpose of Review

Recent Findings

Summary